Michael Mollerus

Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of Applied Therapeutics, Inc., including 411,223 shares of common…

Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Embotelladora Andina S.A. of an aggregate principal amount of $300 million of 3.950%…

Davis Polk is advising Clarivate Analytics plc in connection with its $950 million acquisition of Decision Resources Group from Piramal Enterprises Limited. The $950 million purchase price…

Davis Polk is advising Bertelsmann SE & Co. KGaA on its $675 million acquisition of the stake it did not hold in Penguin Random House. Bertelsmann acquired the remaining 25% stake held…

Davis Polk advised Clarivate Analytics plc in connection with the $857 million SEC-registered secondary offering of 49,680,000 of its ordinary shares by certain funds affiliated with Onex…

Davis Polk advised the joint book-running managers on an SEC-registered offering by The Western Union Company of $500 million aggregate principal amount of its 2.850% notes due 2025. …

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,487,500 shares of common stock of…

Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to…

Davis Polk advised Clarivate Analytics plc in connection with the refinancing of its existing credit facility and unsecured senior notes pursuant to which its indirect wholly owned…